A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Public ClinicalTrials.gov record NCT04244552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.
Study identification
- NCT ID
- NCT04244552
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 87 participants
Conditions and interventions
Conditions
- Breast Cancer
- Colorectal Cancer
- Ovarian Cancer
- Non-Small Cell Lung Cancer
- Acral Lentiginous Melanoma
- Head and Neck Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Esophageal Squamous Cell Carcinoma
- Urothelial Carcinoma
- DMMR Colorectal Cancer
- MSI-H Colorectal Cancer
- Melanoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Epithelial Ovarian Cancer
- Triple Negative Breast Cancer
Interventions
- ATRC-101 Biological
- Pembrolizumab Biological
- Pegylated liposomal doxorubicin (PLD) Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 11, 2020 (Actual)
- Primary completion
- Nov 1, 2023 (Actual)
- Completion
- Nov 1, 2023 (Actual)
- Last update posted
- Dec 29, 2023
2020 – 2023
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| The University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of California, Los Angeles Hematology/Oncology | Los Angeles | California | 90095 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Florida Cancer Specialists | Lake Mary | Florida | 32746 | — |
| University of Miami Hospital - Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic | Rochester | Minnesota | 55902 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Oncology Specialists of Charlotte | Charlotte | North Carolina | 28207 | — |
| Carolina BioOncology | Huntersville | North Carolina | 28078 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Stephenson Cancer Center, University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Oncology Consultants, PLLC | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04244552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 29, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04244552 live on ClinicalTrials.gov.